<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37345346</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Sensitivity and specificity of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised to detect dysarthria in individuals with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>296</StartPage><EndPage>302</EndPage><MedlinePgn>296-302</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27923</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Given the widespread use of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) to measure disease progression in ALS and recent reports demonstrating its poor sensitivity, we aimed to determine the sensitivity and specificity of the ALSFRS-R bulbar subscale and speech item to detect validated clinical ratings of dysarthria in individuals with ALS.</AbstractText><AbstractText Label="METHODS">Paired ALSFRS-R and validated Speech Intelligibility Test (SIT) data from individuals with ALS were analyzed. Trained raters completed duplicate, independent, and blinded ratings of audio recordings to obtain speech intelligibility (%) and speaking rate (words per minute, WPM). Binary dysarthria profiles were derived (dysarthria&#x2009;&#x2264;96% intelligible and/or&#x2009;&lt;150 WPM). Data were obtained using the Kruskal-Wallis test, receiver-operating characteristic (ROC) curve, area under the curve (AUC), sensitivity and specificity percentages, and positive/negative predictive values (PPV/NPV).</AbstractText><AbstractText Label="RESULTS">A total of 250 paired SIT and ALSFRS-R data points were analyzed. Dysarthria was confirmed in 72.4% (n&#x2009;=&#x2009;181). Dysarthric speakers demonstrated lower ALSFRS-R bulbar subscale (8.9 vs. 11.2) and speech item (2.7 vs. 3.7) scores (P&#x2009;&lt;&#x2009;.0001). The ALSFRS-R bulbar subscale score had an AUC of 0.81 (95% confidence interval [CI] 0.75 to 0.86). A subscale score of &#x2264;11 yielded a sensitivity of 86%, specificity of 57%, PPV of 84%, and NPV of 60% to correctly identify dysarthria status. The ALSFRS-R speech item score demonstrated an AUC of 0.81 to detect dysarthria (95% CI 0.76 to 0.85), with sensitivity of 79%, specificity of 75%, PPV of 89%, and NPV of 58% for a speech item cutpoint of &#x2264;3.</AbstractText><AbstractText Label="DISCUSSION">The ALSFRS-R bulbar and speech item subscale scores may be useful, inexpensive, and quick tools for monitoring dysarthria status in ALS.</AbstractText><CopyrightInformation>&#xa9; 2023 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Cara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5546-6081</Identifier><AffiliationInfo><Affiliation>Aerodigestive Research Core Laboratory, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Speech, Language, and Hearing Sciences, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Breathing Research and Therapeutics Center, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hearing and Speech Sciences, Vanderbilt University, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapin</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Aerodigestive Research Core Laboratory, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Speech, Language, and Hearing Sciences, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Amber</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Aerodigestive Research Core Laboratory, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Speech, Language, and Hearing Sciences, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiBiase</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Aerodigestive Research Core Laboratory, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Speech, Language, and Hearing Sciences, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Lauren Tabor</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Aerodigestive Research Core Laboratory, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Speech, Language, and Hearing Sciences, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Breathing Research and Therapeutics Center, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Collaborative Research, NOVA Southeastern University, Fort Lauderdale, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wymer</LastName><ForeName>James P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plowman</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials><Identifier Source="ORCID">0000-0002-0198-4297</Identifier><AffiliationInfo><Affiliation>Aerodigestive Research Core Laboratory, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Speech, Language, and Hearing Sciences, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Breathing Research and Therapeutics Center, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS100859</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004401" MajorTopicYN="N">Dysarthria</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">dysarthria</Keyword><Keyword MajorTopicYN="N">neurogenerative disease</Keyword><Keyword MajorTopicYN="N">screening</Keyword><Keyword MajorTopicYN="N">speech</Keyword></KeywordList><CoiStatement><b>Disclosure of Conflicts of Interest:</b> None of the authors has any conflict of interest to disclose</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37345346</ArticleId><ArticleId IdType="mid">NIHMS1912933</ArticleId><ArticleId IdType="pmc">PMC10529444</ArticleId><ArticleId IdType="doi">10.1002/mus.27923</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hecht M, Hillemacher T, Gr&#xe4;sel E, et al. Subjective experience and coping in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(4):225&#x2013;231. doi:10.1080/146608202760839009</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608202760839009</ArticleId><ArticleId IdType="pubmed">12710513</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite Neto L, Constantini AC. Dysarthria and quality of life in patients with amyotrophic lateral sclerosis. Rev CEFAC. 2017;19(5):664&#x2013;673. doi:10.1590/1982-021620171954017</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1982-021620171954017</ArticleId></ArticleIdList></Reference><Reference><Citation>da Costa Franceschini A, Mour&#xe3;o LF. Dysarthria and dysphagia in Amyotrophic Lateral Sclerosis with spinal onset: a study of quality of life related to swallowing. NeuroRehabilitation. 2015;36(1):127&#x2013;134. doi:10.3233/NRE-141200</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/NRE-141200</ArticleId><ArticleId IdType="pubmed">25547774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball LJ, Beukelman DR, Pattee GL. Timing of speech deterioration in people with amyotrophic lateral sclerosis. Journal of Medical Speech. 2002.</Citation></Reference><Reference><Citation>Yorkston KM. Speech deterioration in amyotrophic lateral sclerosis: Implications for the timing of intervention. Jounal of Medical Speech. 1993.</Citation></Reference><Reference><Citation>Green JR, Yunusova Y, Kuruvilla MS, et al. Bulbar and speech motor assessment in ALS: challenges and future directions. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7&#x2013;8):494&#x2013;500. doi:10.3109/21678421.2013.817585</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.817585</ArticleId><ArticleId IdType="pmc">PMC3833808</ArticleId><ArticleId IdType="pubmed">23898888</ArticleId></ArticleIdList></Reference><Reference><Citation>Beukelman D, Fager S, Nordness A. Communication Support for People with ALS. Neurol Res Int. 2011;2011:714693. doi:10.1155/2011/714693</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/714693</ArticleId><ArticleId IdType="pmc">PMC3096454</ArticleId><ArticleId IdType="pubmed">21603029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball LJ, Beukelman DR, Pattee GL. Communication effectiveness of individuals with amyotrophic lateral sclerosis. J Commun Disord. 2004;37(3):197&#x2013;215. doi:10.1016/j.jcomdis.2003.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcomdis.2003.09.002</ArticleId><ArticleId IdType="pubmed">15063143</ArticleId></ArticleIdList></Reference><Reference><Citation>Helleman J, Kruitwagen ET, van den Berg LH, Visser-Meily JMA, Beelen A. The current use of telehealth in ALS care and the barriers to and facilitators of implementation: a systematic review. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(3&#x2013;4):167&#x2013;182. doi:10.1080/21678421.2019.1706581</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1706581</ArticleId><ArticleId IdType="pubmed">31878794</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombaci A, Abbadessa G, Trojsi F, et al. Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail. Neurol Sci. 2021;42(1):9&#x2013;13. doi:10.1007/s10072-020-04783-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04783-x</ArticleId><ArticleId IdType="pmc">PMC7538170</ArticleId><ArticleId IdType="pubmed">33025327</ArticleId></ArticleIdList></Reference><Reference><Citation>Haulman A, Geronimo A, Chahwala A, Simmons Z. The use of telehealth to enhance care in ALS and other neuromuscular disorders. Muscle Nerve. 2020;61(6):682&#x2013;691. doi:10.1002/mus.26838</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26838</ArticleId><ArticleId IdType="pubmed">32297678</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegmann GM, Hahn S, Duncan CJ, et al. Estimation of forced vital capacity using speech acoustics in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(sup1):14&#x2013;21. doi:10.1080/21678421.2020.1866013</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1866013</ArticleId><ArticleId IdType="pubmed">34348537</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegmann GM, Hahn S, Liss J, et al. Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysis. npj Digital Med. 2020;3:132. doi:10.1038/s41746-020-00335-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00335-x</ArticleId><ArticleId IdType="pmc">PMC7555482</ArticleId><ArticleId IdType="pubmed">33083567</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci. 1997;152 Suppl 1:S1&#x2013;9. doi:10.1016/s0022-510x(97)00237-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(97)00237-2</ArticleId><ArticleId IdType="pubmed">9419047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21. doi:10.1016/S0022-510X(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Plowman EK, Tabor LC, Wymer J, Pattee G. The evaluation of bulbar dysfunction in amyotrophic lateral sclerosis: survey of clinical practice patterns in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(5&#x2013;6):351&#x2013;357. doi:10.1080/21678421.2017.1313868</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1313868</ArticleId><ArticleId IdType="pmc">PMC7001984</ArticleId><ArticleId IdType="pubmed">28425762</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, de Jongh AD, Nikolakopoulos S, et al. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(3&#x2013;4):300&#x2013;307. doi:10.1080/21678421.2021.1879865</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1879865</ArticleId><ArticleId IdType="pubmed">33527843</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapin JL, Gray LT, Vasilopoulos T, et al. Diagnostic utility of the amyotrophic lateral sclerosis Functional Rating Scale-Revised to detect pharyngeal dysphagia in individuals with amyotrophic lateral sclerosis. PLoS One. 2020;15(8):e0236804. doi:10.1371/journal.pone.0236804</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0236804</ArticleId><ArticleId IdType="pmc">PMC7425890</ArticleId><ArticleId IdType="pubmed">32790801</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88(5):381&#x2013;385. doi:10.1136/jnnp-2016-314661</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314661</ArticleId><ArticleId IdType="pubmed">27888187</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB. Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12(2):384&#x2013;393. doi:10.1007/s13311-014-0331-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0331-9</ArticleId><ArticleId IdType="pmc">PMC4404434</ArticleId><ArticleId IdType="pubmed">25582382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacci ED, Staniewska D, Coyne KS, et al. Item response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials Database. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3&#x2013;4):157&#x2013;167. doi:10.3109/21678421.2015.1095930</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1095930</ArticleId><ArticleId IdType="pubmed">26473473</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mandrioli J, Giordano A, Ferro S, ERRALS Group. A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5&#x2013;6):331&#x2013;337. doi:10.3109/21678421.2015.1026829</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1026829</ArticleId><ArticleId IdType="pubmed">25916346</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mora G, Giordano A, Volanti P, Chi&#xf2; A. Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. 2013;84(12):1340&#x2013;1345. doi:10.1136/jnnp-2012-304701</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304701</ArticleId><ArticleId IdType="pubmed">23516308</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. doi:10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Stipancic KL, Yunusova Y, Berry JD, Green JR. Minimally detectable change and minimal clinically important difference of a decline in sentence intelligibility and speaking rate for individuals with amyotrophic lateral sclerosis. J Speech Lang Hear Res. 2018;61(11):2757&#x2013;2771. doi:10.1044/2018_JSLHR-S-17-0366</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/2018_JSLHR-S-17-0366</ArticleId><ArticleId IdType="pmc">PMC6693567</ArticleId><ArticleId IdType="pubmed">30383220</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison KM, Yunusova Y, Green JR. Shorter sentence length maximizes intelligibility and speech motor performance in persons with dysarthria due to amyotrophic lateral sclerosis. Am J Speech Lang Pathol. 2019;28(1):96&#x2013;107. doi:10.1044/2018_AJSLP-18-0049</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/2018_AJSLP-18-0049</ArticleId><ArticleId IdType="pmc">PMC6503867</ArticleId><ArticleId IdType="pubmed">31072158</ArticleId></ArticleIdList></Reference><Reference><Citation>Robison R, DiBiase L, Ashley A, et al. Swallowing Safety and Efficiency Impairment Profiles in Individuals with Amyotrophic Lateral Sclerosis. Dysphagia. 2022;37(3):644&#x2013;654. doi:10.1007/s00455-021-10315-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00455-021-10315-2</ArticleId><ArticleId IdType="pmc">PMC8617061</ArticleId><ArticleId IdType="pubmed">34037850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruoppolo G, Onesti E, Gori MC, et al. Laryngeal Sensitivity in Patients with Amyotrophic Lateral Sclerosis. Front Neurol. 2016;7:212. doi:10.3389/fneur.2016.00212</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2016.00212</ArticleId><ArticleId IdType="pmc">PMC5124602</ArticleId><ArticleId IdType="pubmed">27965622</ArticleId></ArticleIdList></Reference><Reference><Citation>Plowman EK, Tabor LC, Robison R, Wymer J. Delineating mechanisms of dysphagia in ALS. ALS FTD. 2016.</Citation></Reference><Reference><Citation>Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11(1&#x2013;2):178&#x2013;180. doi:10.3109/17482960903093710</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903093710</ArticleId><ArticleId IdType="pubmed">19634063</ArticleId></ArticleIdList></Reference><Reference><Citation>Miano B, Stoddard GJ, Davis S, Bromberg MB. Inter-evaluator reliability of the ALS functional rating scale. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(4):235&#x2013;239. doi:10.1080/14660820410021302</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410021302</ArticleId><ArticleId IdType="pubmed">15799553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis EJ, Dempsey-Hall L, Thompson MM, Luu LC, Mendiondo M, Kryscio R. Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(1):50&#x2013;54. doi:10.1080/14660820510027107</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820510027107</ArticleId><ArticleId IdType="pubmed">16036426</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>